NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma

Phase 1

Active, not recruiting

Conditions: Resectable Soft Tissue Sarcoma
Soft Tissue Sarcoma

Interventions: Drug: Navtemadlin
Radiation: Radiation Therapy
Procedure: Surgical Procedure

First Posted Date: 2017-07-14

Last Posted Date: 2025-03-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 39

Registration Number: NCT03217266

Locations: 🇺🇸
Logan Health Medical Center, Kalispell, Montana, United States
🇺🇸
CTCA at Western Regional Medical Center, Goodyear, Arizona, United States
🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States

and more 50 locations

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

Phase 2

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
Recurrent Ependymoma
Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Recurrent Glioma
Recurrent Hepatoblastoma
Recurrent Kidney Wilms Tumor
Recurrent Langerhans Cell Histiocytosis
Recurrent Malignant Germ Cell Tumor
Recurrent Malignant Glioma
Recurrent Malignant Solid Neoplasm

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration and Biopsy
Procedure: Bone Scan
Procedure: Computed Tomography
Drug: Larotrectinib Sulfate
Procedure: Magnetic Resonance Imaging
Procedure: Radionuclide Imaging
Procedure: X-Ray Imaging

First Posted Date: 2017-07-11

Last Posted Date: 2025-05-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 9

Registration Number: NCT03213704

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States
🇺🇸
Banner Children's at Desert, Mesa, Arizona, United States

and more 121 locations

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

Phase 2

Active, not recruiting

Conditions: Glioblastoma
Recurrent Cholangiocarcinoma
WHO Grade 2 Glioma
Recurrent Glioma
Advanced Malignant Solid Neoplasm
Recurrent Malignant Solid Neoplasm
WHO Grade 3 Glioma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Drug: Olaparib

First Posted Date: 2017-07-11

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 145

Registration Number: NCT03212274

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 48 locations

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

Phase 2

Completed

Conditions: Ann Arbor Stage III Hodgkin Lymphoma
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Recurrent Hodgkin Lymphoma
Ann Arbor Stage III Non-Hodgkin Lymphoma
Low Grade Glioma
Recurrent Ewing Sarcoma
Recurrent Langerhans Cell Histiocytosis
Recurrent Malignant Glioma
Recurrent Rhabdomyosarcoma
Refractory Malignant Glioma

Interventions: Drug: Tazemetostat

First Posted Date: 2017-07-11

Last Posted Date: 2025-01-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT03213665

Locations: 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States

and more 114 locations

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Phase 2

Completed

Conditions: Advanced Malignant Solid Neoplasm
Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
Refractory Primary Central Nervous System Neoplasm
Recurrent Childhood Central Nervous System Neoplasm
Recurrent Neuroblastoma
Recurrent Childhood Non-Hodgkin Lymphoma
Recurrent Malignant Solid Neoplasm
Refractory Neuroblastoma
Refractory Malignant Solid Neoplasm

Interventions: Other: Laboratory Biomarker Analysis
Drug: Selumetinib
Drug: Selumetinib Sulfate

First Posted Date: 2017-07-11

Last Posted Date: 2025-02-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT03213691

Locations: 🇵🇷
University Pediatric Hospital, San Juan, Puerto Rico
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Banner Children's at Desert, Mesa, Arizona, United States

and more 107 locations

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

Phase 2

Completed

Conditions: Ann Arbor Stage III Non-Hodgkin Lymphoma
Recurrent Glioma
Recurrent Hepatoblastoma
Recurrent Langerhans Cell Histiocytosis
Recurrent Malignant Solid Neoplasm
Recurrent Osteosarcoma
Stage III Osteosarcoma AJCC v7
Stage IV Soft Tissue Sarcoma AJCC v7
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Recurrent Malignant Germ Cell Tumor

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: FDG-Positron Emission Tomography
Procedure: Magnetic Resonance Imaging
Drug: Samotolisib
Procedure: X-Ray Imaging

First Posted Date: 2017-07-11

Last Posted Date: 2025-01-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT03213678

Locations: 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Banner University Medical Center - Tucson, Tucson, Arizona, United States

and more 124 locations

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Phase 2

Active, not recruiting

Conditions: Recurrent Malignant Glioma
Recurrent Neuroblastoma
Malignant Solid Neoplasm
Recurrent Medulloblastoma
Recurrent Rhabdoid Tumor
Recurrent Soft Tissue Sarcoma
Refractory Malignant Germ Cell Tumor
Refractory Malignant Solid Neoplasm
Refractory Rhabdoid Tumor
Advanced Malignant Solid Neoplasm

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration and Biopsy
Procedure: Bone Scan
Procedure: Computed Tomography
Drug: Ensartinib
Other: Laboratory Biomarker Analysis
Procedure: Magnetic Resonance Imaging
Other: Pharmacological Study
Procedure: Positron Emission Tomography
Procedure: Radionuclide Imaging
Procedure: X-Ray Imaging

First Posted Date: 2017-07-11

Last Posted Date: 2025-04-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 98

Registration Number: NCT03213652

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States
🇺🇸
Banner Children's at Desert, Mesa, Arizona, United States

and more 124 locations

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Phase 2

Active, not recruiting

Conditions: Recurrent Childhood Non-Hodgkin Lymphoma
Recurrent Childhood Malignant Germ Cell Tumor
Recurrent Childhood Rhabdomyosarcoma
Recurrent Childhood Soft Tissue Sarcoma
Advanced Malignant Solid Neoplasm
Recurrent Childhood Osteosarcoma
Recurrent Childhood Ependymoma
Recurrent Childhood Medulloblastoma
Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Recurrent Hepatoblastoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration and Biopsy
Procedure: Bone Scan
Procedure: Computed Tomography
Drug: Erdafitinib
Other: Laboratory Biomarker Analysis
Procedure: Magnetic Resonance Imaging
Other: Pharmacological Study
Procedure: Positron Emission Tomography
Procedure: Radionuclide Imaging
Procedure: X-Ray Imaging

First Posted Date: 2017-07-07

Last Posted Date: 2025-04-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT03210714

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States
🇺🇸
Banner Children's at Desert, Mesa, Arizona, United States

and more 113 locations

A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer
Colorectal Carcinoma
Colorectal Adenocarcinoma
Refractory Cancer
Colorectal Neoplasms

Interventions: Drug: Durvalumab
Drug: Tremelimumab
Biological: Pexa-Vec

First Posted Date: 2017-07-02

Last Posted Date: 2023-10-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 34

Registration Number: NCT03206073

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1

Completed

Conditions: Recurrent Primary Peritoneal Carcinoma
Platinum-Resistant Ovarian Carcinoma
Platinum-Resistant Primary Peritoneal Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Fallopian Tube Carcinoma
Platinum-Resistant Fallopian Tube Carcinoma

Interventions: Drug: Atezolizumab
Other: Laboratory Biomarker Analysis
Drug: Guadecitabine
Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Drug: Poly ICLC

First Posted Date: 2017-07-02

Last Posted Date: 2025-03-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT03206047

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

and more 14 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy